JP Morgan Chase
NMRA icon

JP Morgan Chase’s Neumora Therapeutics NMRA Stock Holding History

JP Morgan Chase’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-225,000
Closed -$2.38M – 7606
2024
Q4 		$2.38M Buy
+225,000
New +$2.7M ﹤0.01% 4015

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's NMRA Position: Q2 2026 in Review

JP Morgan Chase reduced its Neumora Therapeutics (NMRA) stake by 77% in Q2 2026, selling an estimated $401K and leaving 63,624 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #5976.

JP Morgan Chase first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $14.8M in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • JP Morgan Chase held 63,624 shares of Neumora Therapeutics worth $109K as of Q2 2026.
  • JP Morgan Chase sold 210,479 Neumora Therapeutics shares in Q2 2026, an estimated $401K.
  • Neumora Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5976 holding.
  • JP Morgan Chase first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • JP Morgan Chase's Neumora Therapeutics position peaked at $14.8M in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.